Literature DB >> 7704617

Inhibition of phospholipase C with neomycin improves metabolic and neurologic outcome following traumatic brain injury.

E M Golding1, R Vink.   

Abstract

Activation of phospholipase C has been implicated as a factor in the development of irreversible tissue damage following injury to the central nervous system. We have used phosphorus magnetic resonance spectroscopy and a battery of postinjury motor function tests to characterize the role that phospholipase C activity may play in determining biochemical and neurologic outcome following traumatic brain injury in rats. Moderate (2.7 atmospheres) fluid percussion induced lateral brain injury caused a decline in free magnesium concentration, phosphorylation potential, and increased mitochondrial rate of oxidative phosphorylation. Neurologic motor score at 24 h and 1 week posttrauma in these animals was consistent with moderate injury. In contrast, treatment with the phospholipase C inhibitor neomycin B (15 mg/kg i.v.) immediately prior to injury significantly improved free magnesium status, bioenergetic state and neurological outcome (P < 0.01) after injury. We propose that phospholipase C activated second messenger pathways affecting magnesium homeostasis are involved in determining outcome after brain injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7704617     DOI: 10.1016/0006-8993(94)90509-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Tandem regulation of phosphoinositide signaling and acute behavioral effects induced by antidepressant agents in rats.

Authors:  Kimberly R Tyeryar; Ashiwel S Undie
Journal:  Psychopharmacology (Berl)       Date:  2007-04-15       Impact factor: 4.415

2.  High interindividual variability in dose-dependent reduction in speed of movement after exposing C. elegans to shock waves.

Authors:  Nicholas B Angstman; Maren C Kiessling; Hans-Georg Frank; Christoph Schmitz
Journal:  Front Behav Neurosci       Date:  2015-02-06       Impact factor: 3.558

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.